



PRIOR AUTHORIZATION REQUEST FORM  
CLOSTRIDIUM DIFFICILE DRUGS

Dificid®, Zinplava™

For authorization, please answer each question and fax this form PLUS chart notes back to Real Rx at 385-425-4052.

Failure to submit clinical documentation to support this request will result in a dismissal of the request.

If you have prior authorization questions, please call for assistance 385-425-5094.

Disclaimer: Prior authorization request forms are subject to change in accordance with Federal and State notice requirements.

Date:	Member Name:	ID#:
DOB:	Gender:	Physician:
Office Phone:	Office Fax:	Office Contact:

Height/Weight:

Member must try formulary preferred drugs before a request for a non-preferred drug may be considered. If treatment with preferred products has not been successful, you must submit which preferred products have been tried, dates of treatment, and reason for failure. Reasons for failure must meet the Health Plan medical necessity criteria.

Product being requested:  Dificid® (fidaxomicin),  Zinplava™ (bezlotuxumab)

Dosing/Frequency: \_\_\_\_\_

Questions	Yes	No	Comments/Notes
1. Is this request for an <b>expedited</b> review? By checking the “ <b>Yes</b> ” box to request an expedited review (24 hours), you are certifying that applying the standard review time frame (72 hours) may place the member's life, health, or ability to regain maximum function in serious jeopardy.	<input type="checkbox"/>	<input type="checkbox"/>	
<b>DIFICID®</b>			
1. Does the member have a diagnosis of C. difficile based on diarrheal symptoms AND a current positive stool toxin test?	<input type="checkbox"/>	<input type="checkbox"/>	<b>Please provide documentation</b>
2. If this is for an initial episode, does documentation show a trial and failure of at least 10 days of oral vancomycin?	<input type="checkbox"/>	<input type="checkbox"/>	<b>Please provide documentation</b>
3. If the request is for recurrent C. difficile, does documentation show a trial and failure of pulsed or tapered vancomycin regimen OR a second 10-day course of vancomycin?	<input type="checkbox"/>	<input type="checkbox"/>	<b>Please provide documentation</b>
<b>ZINPLAVA™</b>			
1. Is the request for prophylaxis therapy with Zinplava™?	<input type="checkbox"/>	<input type="checkbox"/>	
2. Does the member have a diagnosis of C. difficile based on diarrheal symptoms AND a positive stool toxin test or PCR?	<input type="checkbox"/>	<input type="checkbox"/>	<b>Please provide documentation</b>
3. Has the member had at least 2 confirmed recurrent C. difficile episodes (3 total) that have been treated with a vancomycin regimen?	<input type="checkbox"/>	<input type="checkbox"/>	<b>Please provide documentation</b>
4. Does documentation show that the second recurrence was treated with pulsed or tapered vancomycin?	<input type="checkbox"/>	<input type="checkbox"/>	<b>Please provide documentation</b>

5. Will the member concurrently receive vancomycin or metronidazole?	<input type="checkbox"/>	<input type="checkbox"/>	
6. Is the member at high risk of C. difficile recurrence by meeting one of the following: <ul style="list-style-type: none"> <li>• Age ≥ 65 years</li> <li>• History of C. difficile infection in the past 6 months</li> <li>• Immunocompromised state</li> <li>• C. diff ribotype 027</li> <li>• Severe C. difficile infection at presentation with white blood cell ≥15,000 cells/mm<sup>3</sup> OR serum creatinine &gt; 1.5g/dL</li> </ul>	<input type="checkbox"/>	<input type="checkbox"/>	<b>Please provide documentation</b>
<b>REAUTHORIZATION</b>			
1. Is the request for reauthorization of Difucid®?	<input type="checkbox"/>	<input type="checkbox"/>	
2. Does updated documentation show continued medical need and tolerance of therapy?	<input type="checkbox"/>	<input type="checkbox"/>	<b>Please provide documentation</b>
<b>What medications and/or treatment modalities have been tried in the past for this condition? Please document name of treatment, reason for failure, treatment dates, etc.</b>			
Additional information:			
Physician Signature:			

**\*\* Failure to submit clinical documentation to support this request will result in a dismissal of the request.\*\***

Policy: PHARM-015  
Origination Date: 02/14/2018  
Reviewed/Revised Date: 03/15/2023  
Next Review Date: 03/15/2024  
Current Effective Date: 04/01/2023

**Confidentiality Notice**

This document and any accompanying document contain confidential information and is intended for the use of the individual or entity named on this transmission sheet. If you are not the intended recipient, you are hereby notified that any disclosure, copying, distribution or the taking of any action in reliance on the contents of this information is strictly prohibited and the document should be returned to this office immediately. If you have received this facsimile in error, please notify us by telephone immediately and destroy document received.